That is according to rumors heard by scott matusow. He has a solid piece published late last week. Here is the write-up:
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that companies were interested in Obagi. Based on the available information I had to work with at the time, I predicted that Obagi would see an acquisition soon.
Because of the delay in the Obagi Acquisition, I have been hesitant to write on other companies I have heard through various sources have acquisition interest. However, in this article I will mention companies I believe will be acquired this year, based on my own speculation and some of the same chatter from the same sources who originally brought Obagi to my attention.
Antares Pharma (ATRS)
Many who follow me both on Seeking Alpha and twitter know that I used to own a good size block of shares in Antares, which I originally purchased in the summer of 2011. In December of the same year, I began to hear chatter than Pfizer (PFE) was interested in acquiring Antares. I did not think much of it at the time, until I saw a short time later that the company made a deal with Pfizer to partner on an unknown over-the-counter drug. I inquired back with my source at the time to ask him how solid the rumor was, and he felt it was "very solid." A few months later, the company "appointed" Jack Howarth, a former King-Pfizer executive, as Vice President of Corporate Affairs.
Based on Jack's above history and timeframe, and with Antares virtually assured approval of its current NDA in submission to the FDA, notwithstanding what sources have informed me in the past, I speculate that Antares will be acquired sometime this summer/early fall.
The main reason I believe Pfizer will acquire Antares is for its patent profile it holds in regards to biosimilars.